ClinicalTrials.Veeva

Menu

Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB (REMOTE)

K

Klinikum Nürnberg

Status

Unknown

Conditions

Hemofiltration
Extracorporeal Circulation

Treatments

Device: Cytosorb Adsorber

Study type

Interventional

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response.

They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery.

Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments.

These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure.

There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay.

Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure.

Full description

In a lot of cases during cardiac surgery cardiopulmonary bypass initiates SIRS due to release of cytokines during immunological response.

They are induced by different types of inductors ( intrinsic and extrinsic). High levels of inflammation markers like TNF-a, IL 6 and IL 10 as well as TGF-ß are detectable after 2 hours of surgery.

Beside the inflammation acute phase parameters like fibrinogen, ferritin are increased. These changes lead to rheology impairments.

These strong reactions lead to dysfunction of different organs possibly culminating in a multi organ failure.

There is a correlation between amounts of cytokines and mortality. Often AKI occurs after CPB with a rate of about 30%. Dysfunctions of organ function are often connected with increased mortality, prolonged mechanical ventilation , septic complications, increased catecholamine dosages and prolonged length of ICU stay.

Use of cytokine adsorption within the extracorporeal circuit during CBP can affect the circulating cytokine levels during and after CPB and lead to a diminished inflammatory response, acute phase reaction as well as reduction of organ failure.

Official Title: Removal of Cytokines in patients undergoing cardiac surgery with CPB ( The REMOTE Study)

Study type: Interventional Study design: randomized, controlled Endpoint Classification: Efficacy study Interventional Model: Parallel assignment Masking: Single blinding ( Subject) Primary purpose: Treatment

Patients who have an elective cardiac surgery with an expected CPB duration > 75 min ( e.g. valve surgery, CABG, combined procedures, redo) will be enrolled into the study after a giving informed consent.

Selection of patients are directed by randomization. Patient which drop out will be replaced.

Enrollment

80 estimated patients

Sex

All

Ages

65 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Elective cardiac surgery with CPB
  • Signed informed consent
  • CPB time > 75 min.
  • Comorbidities:
  • diabetes mellitus
  • CHF, NYHA class 1 and 2
  • liver dysfunction (1, 2)
  • kidney dysfunction (1, 2)
  • hypertension
  • arteriosclerosis

Exclusion criteria

  • Age < 65 years
  • Declined informed consent
  • Planed temperature < 32 C
  • Emergency surgery
  • Preexisting renal replacement therapy
  • Preexisting kidney transplantation
  • Administration of immunosuppressants like steroids
  • AIDS with CD 4 < 200/
  • Participation in other trials

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

80 participants in 2 patient groups

Treatment
Experimental group
Description:
CPB with Cytosorb
Treatment:
Device: Cytosorb Adsorber
Control
No Intervention group
Description:
CPB without Cytosorb (Control)

Trial contacts and locations

1

Loading...

Central trial contact

Giuseppe Santarpino, MD; Theodor Fischlein, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems